000			02474nam a22003497a 4500
008			210217s20202020 xxu||||| |||| 00| 0 eng d
022			_a1758-8340
024			_a10.1177_1758835920980365 [pii]
024			_a10.1177/1758835920980365 [doi]
024			_aPMC7750570 [pmc]
040			_aOvid MEDLINE(R)
099			_a33414848
245			_aChemo-immunotherapy as first-line treatment for small-cell lung cancer. [Review]
251			_aTherapeutic Advances in Medical Oncology. 12:1758835920980365, 2020.
252			_aTher Adv Med Oncol. 12:1758835920980365, 2020.
253			_aTherapeutic advances in medical oncology
260			_c2020
260			_fFY2021
265			_sepublish
266			_d2021-02-17
520			_aSmall-cell lung cancer (SCLC) is a highly lethal subtype of lung cancer. Despite concerted efforts over the past several decades, there have been limited therapeutic advances. Traditional chemotherapy offers a high response rate and rapid symptomatic improvement, but its benefit is fleeting, and relapse is quick and unforgiving. Immunotherapy has delivered improved outcomes for patients with many cancers and there was compelling rationale for development in SCLC. While initial efforts with cytotoxic T-lymphocyte protein-4 inhibitors failed to improve upon chemotherapy alone, the addition of programmed death ligand-1 (PD-L1) inhibitors to first-line chemotherapy finally provided long-awaited gains in survival. Atezolizumab, when added to carboplatin and etoposide, improved both progression-free survival and overall survival. Durvalumab, when added to platinum plus etoposide, similarly improved OS. Biomarker development has stalled as PD-L1 expression and tumor mutational burden have not been useful predictive biomarkers. However, based on the significant survival improvements, both atezolizumab and durvalumab were approved by the US Food and Drug Administration to be given with first-line chemotherapy, and these regimens represent the new standards of care for SCLC. Copyright (c) The Author(s), 2020.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Washington Hospital Center
656			_aMedicine/General Internal Medicine
657			_aJournal Article
657			_aReview
700			_aFarid, Saira
790			_aFarid S, Liu SV
856			_uhttps://dx.doi.org/10.1177/1758835920980365 _zhttps://dx.doi.org/10.1177/1758835920980365
942			_cART _dArticle
999			_c6118 _d6118